Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip
Engineered live bacteria could represent a new class of therapeutic treatment for human disease. Here, the authors use a human gut-on-a-chip microfluidics system to characterize an engineered live bacterial therapeutic, designed for the treatment of phenylketonuria, and to construct mathematical mod...
Guardado en:
Autores principales: | M. Tyler Nelson, Mark R. Charbonneau, Heidi G. Coia, Mary J. Castillo, Corey Holt, Eric S. Greenwood, Peter J. Robinson, Elaine A. Merrill, David Lubkowicz, Camilla A. Mauzy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/229bd7533d5f4591b5fea3903111b0fd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria
por: Mark R. Charbonneau, et al.
Publicado: (2021) -
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
por: Cary O Harding
Publicado: (2010) -
Italian national consensus statement on management and pharmacological treatment of phenylketonuria
por: Alberto Burlina, et al.
Publicado: (2021) -
Protein status of people with phenylketonuria: a scoping review protocol
por: Kevin Whelan, et al.
Publicado: (2021) -
Developing a new class of engineered live bacterial therapeutics to treat human diseases
por: Mark R. Charbonneau, et al.
Publicado: (2020)